GLG News by Physicians who Treat Ankylosing Spondylitis (US)

Patient autonomy is one of the key principles of bioethics.  It follows that patients have the right to maintain their own health record as this provides them with knowledge to make educated decisions and facilitates encounters with multiple physicians. Physicians can still maintain their own...

The principles look sound and should thwart all but the most sophisticated addicts. It would probably take good knowledge of organic chemistry to separate the two components.  Unfortunately, this will all come with increased cost over conventional 'unprotected' opiates and struggles ...

Will the sale of Celebrex be hurt by a rehashing of old data? Overly simplified negative news coverage frightens patients and reduces those willing to take the drug.  If they should agree to take it after counseling and be one of those who suffer a heart attack for what ever...

This should not deter the practicing physician to prescribe these agents osteoporosis will reach epidemic proportions and if we can reduce fractures by 50% the savings within the healthcare system will be enormous that's not to say that individuals albeit rare may have a propensity to develop fractures...

1. This study may not have a big impact on the prescriptions of alendronate in the short term unless this problem is found to be more wide-spread. With the increased incidence of jaw necrosis reported earlier, physicians will carefully weigh the benefits before starting alendronate. 2. The fractures...

That the ADAPT Study found no improvement in cognitive function in subjects who took the NSAID naproxen or celecoxib, a COX2 inhibitor, compared to subjects taking placebo, is hardly surprising.  Subjects were age 70 and older, with a family history of Alzheimer's disease.  Previous...

More contradictory data.  But without a clear case, it does not make sense to prescribe NSAIDS to patients with AD.

Rituxan is no better than placebo in SLE in this study.  Another med bites the dust when tested for SLE.  Further details of this study need to be reviewed.

The problem with lupus studies lies in study design.  While true for all trials, this is specially true for lupus since the disease is not "uniform".  Patients have so many different varieties of lupus that the inclusion/exclusion criteria can make or break a study before it starts.

IL-7 is important for B and T cell development.  But both cells require multiple cytokines, in the correct chronological order and appropriate amounts, for optimum results.